Prestige Consumer Healthcare's quarterly market cap
declined
from Sep. 2025 ($3,000 Mil) to Dec. 2025 ($2,919 Mil) and
declined
from Dec. 2025 ($2,919 Mil) to Mar. 2026 ($2,805 Mil).
Prestige Consumer Healthcare's annual market cap
increased
from Mar. 2024 ($3,615 Mil) to Mar. 2025 ($4,256 Mil) but then
declined
from Mar. 2025 ($4,256 Mil) to Mar. 2026 ($2,805 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Prestige Consumer Healthcare's Enterprise Value for Today is $3,269 Mil.
Prestige Consumer Healthcare (NYSE:PBH) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Prestige Consumer Healthcare Market Cap Related Terms
Prestige Consumer Healthcare Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prestige Consumer Healthcare Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's Market Cap distribution charts can be found below:
* The bar in red indicates where Prestige Consumer Healthcare's Market Cap falls into.
Prestige Consumer Healthcare Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prestige Consumer Healthcare (PBH) has a Market Cap of $2,288 Mil as of Jul. 09, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Prestige Consumer Healthcare and its competitors. According to the industry distribution chart, Prestige Consumer Healthcare ranks #140 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 13.7%.
Is Prestige Consumer Healthcare's Market Cap too high?
Prestige Consumer Healthcare's current Market Cap is $2,288 Mil. The Drug Manufacturers industry median Market Cap is 210.75. Prestige Consumer Healthcare's value of $2,288 Mil is 985.7% above this industry median. Based on the distribution chart, Prestige Consumer Healthcare ranks #140 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Prestige Consumer Healthcare has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's Market Cap compare to BCRX and AMLX?
According to the Drug Manufacturers industry distribution chart, Prestige Consumer Healthcare ranks #140 out of 1024 companies for Market Cap. This places Prestige Consumer Healthcare in the top 14% of its industry — outperforming the majority of peers. The industry median Market Cap is 210.75. Prestige Consumer Healthcare's value of $2,288 Mil is 985.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 210.75, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prestige Consumer Healthcare's current Market Cap of $2,288 Mil is 985.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Prestige Consumer Healthcare and its competitors. For the Drug Manufacturers industry, the median Market Cap is 210.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prestige Consumer Healthcare's current Market Cap is $2,288 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (PBH) is currently considered Modestly Undervalued. The stock's GF Value™ is $68.39, compared to a current price of $48.29 — trading 29.4% below its estimated fair value. The current Market Cap is $2,288 Mil and 985.7% above the Drug Manufacturers industry median of 210.75. Prestige Consumer Healthcare's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Prestige Consumer Healthcare (PBH), the current Market Cap is $2,288 Mil as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prestige Consumer Healthcare (PBH) Overvalued in 2026?
Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued.
The current stock price of $48.29 is trading 29.4% below its estimated GF Value™ of $68.39.
GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.
Key valuation signals for PBH:
Market Cap: $2,288 Mil
GF Value™: $68.39 vs. price of $48.29 (29.4% below fair value)
Industry Position: 985.7% above the Drug Manufacturers median (#140 of 1024)
No single metric tells the full story. See the PBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
68GF Score
Get the complete analysis for PBH
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBH has been successfully added to your 
